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For many years, the importance of preser-
vation injury has been under-recognized 
in kidney transplantation — delayed 
graft  function (DGF) was seen as a phe-
nomenon with little or no long-term 
consequences following kidney trans-
plantation. Now, however, an important 
association is recognized between DGF 
and poor outcome: there is a higher 
rate of chronic allograft nephropathy 
and fi ve-year graft  survival is reduced.1 
Concerns over the longer-term eff ects of 
acute tubular necrosis (the underlying 
injury in DGF) have been raised further 
with the increasing use of kidneys from 
non-heart-beating donors — kidneys that 
are removed aft er circulatory arrest and 
therefore undergo an inevitable period of 
warm ischemia before cold preservation. 
Th ere is thus now much more interest in 
kidney preservation than previously.
In this issue, Ahmad et al. present in 
vivo functional data to demonstrate that 
immediate renal function after warm 
ischemic injury is infl uenced by the choice 
of preservation solution.2 Th ey used an 
in vivo model to study protection of the 
kidney during 45 minutes of normother-
mic ischemia and 2 hours of reperfusion. 
PBS140, a simple formulation of readily 
available and low-cost reagents,3 proved 
to be at least as eff ective as, or superior 
to, the ‘gold standard’ cold preservation 
solution, University of Wisconsin (UW) 
solution, and better than the still widely 
used Euro-Collins and hyperosmolar cit-
rate solutions.
Th is study builds on previous studies 
from the same group, both in vitro using 
an isolated renal proximal tubule prepa-
ration4 and in an in vivo model5 looking 
at PBS140 in comparison with more com-
monly used preservation solutions. Th is 
work showed that during cold ischemia 
PBS140 was the most eff ective preserva-
tion solution, limiting proximal tubule 
cell edema during prolonged cold storage 
and providing maximal protection dur-
ing subsequent simulated warm ischemia. 
Taken together, this series of experiments 
suggests that PBS140 is a good renal pres-
ervation solution, resulting in minimal 
cell edema during cold storage and pro-
viding protection during the rewarming 
phase of transplantation. Now, functional 
data are presented to support the use of 
PBS140 during normothermic ischemia 
— showing that improved protection 
translates to better functional recovery 
in the immediate reperfusion phase. It is 
reasonable to assume that the reduction 
in ischemia/reperfusion injury aff orded 
by PBS140 should result in less delayed 
graft function and, in turn, improved 
long-term graft  survival.
What would it take for a new cold pres-
ervation solution to topple UW solution 
from its position of market dominance? 
It would need to be either signifi cantly 
more eff ective or comparably eff ective 
and signifi cantly cheaper. Although the 
published evidence suggests that PBS140 
may be at least comparable to UW in 
efficacy, data will be required from a 
randomized trial before any real shift  is 
likely in what has traditionally been a 
conservative market. Despite strong evi-
dence from trials in liver transplantation 
published some time previously,6 UW 
solution only became widely used by the 
renal community following the publica-
tion of a large, randomized trial of its use 
in kidney transplantation.7
Although kidney preservation is the 
largest market, it may also be important 
to demonstrate whether any advantage of 
PBS140 is unique to kidneys or whether 
the benefi ts are also seen in all areas of 
solid organ transplantation. Th e future 
of PBS140 in extrarenal preservation 
may, however, be as the basis for a more 
complex preservation solution. Previous 
publications from the same group, using 
isolated rat liver perfusion, have reported 
a benefi cial eff ect of adding lactobionic 
acid8 — this prevented liver weight gain (a 
marker of cell swelling) during cold stor-
age and allowed greater bile production 
and lower enzyme rises on reperfusion. 
Th e addition of 20 mol/l polyethylene 
glycol to standard PBS140 also caused a 
signifi cant decrease in weight gain during 
cold storage and reduced enzymes rises 
on reperfusion in rat liver transplanta-
tion. Polyethylene glycol is thought to 
off er protection from osmotic cell swell-
ing, reduced lipid peroxidation, and 
immune modulation.9
Besides clinical efficacy, the other 
important potential selling point of a 
PBS140 is price. PBS140 is based on low-
cost components and is theoretically 
cheap to manufacture — although if the 
complexity of the solution increases, so 
too will the cost. However, the commer-
cial aspects are more complex: the sell-
ing price of a product refl ects not only the 
cost of components and manufacture, but 
also the large investment in development, 
clinical trials, licensing, and marketing 
and, fi nally, the size of the market. It is 
undoubtedly in the interest of the con-
sumer for there to be competition in any 
market in order to drive down prices; at 
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present the cold preservation market is 
notably short of competitors.
There is now a resurgence of inter-
est in machine perfusion of kidneys 
— continuous pumping of cold solution 
through the kidney. Once a minority 
interest, this technique is now gaining 
acceptance because of an increasingly 
held view that it results in a much lower 
rate of delayed graft  function.10 Clearly 
it will be important to compare PBS140 
with UW solution in conventional kid-
ney transplantation, but it may become 
equally relevant to test it against machine 
perfusion.
The real challenge now lies in the 
preservation of kidneys from marginal 
donors. As the demand for transplanta-
tion increases and the supply of ‘ideal’ 
organs (typically from young, heart-
beating donors) decreases, organs are 
now routinely transplanted from donors 
that would have been rejected in the past. 
Th ese include older donors, those with 
cardiovascular disease, those on large 
doses of inotropic support, and, par-
ticularly, non-heart-beating donors. It is 
this last group that is increasing rapidly, 
partly as a result of changing neurosur-
gical practice. Organs from non-heart-
beating donors experience a period of 
warm ischemia before cold preservation. 
Th is combination of injuries is associated 
with a much higher rate of acute tubular 
necrosis and delayed graft  function. Th e 
results reported by Ahmad et al. in this 
issue are important not just because these 
demonstrate the potential of another 
cold preservation solution, but because 
the experiments were carried out specifi -
cally to investigate preservation during 
warm ischemia — as seen in the situa-
tion of the non-heart-beating donor. It 
is possible that non-heart-beating donor 
renal transplantation will prove to be the 
niche that enables PBS140 to break into 
the preservation market.
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Expression of Toll-like receptors 
in the kidney: their potential role 
beyond infection
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Toll-like receptors (TLRs) recognize both exogenous microbial 
components and endogenous molecules to promote immune 
activation. Both immune and nonimmune renal cells express TLRs, 
which are involved in the pathogenesis of a number of kidney diseases, 
including pyelonephritis, Leptospira nephritis, immune-complex 
glomerulonephritis, ischemic/reperfusion injury, and rejection of 
kidney transplant.
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Th e immune system in mammals consists 
of innate and adaptive immunity. The 
adaptive immune system is a sophisticated 
system mediated by antigen-specifi c T cells 
and B cells. Th e innate immune system is 
phylogenetically conserved and is the fi rst 
line of host defense against pathogenic 
microorganisms. Recently, great interest 
in innate immunity has emerged with the 
discovery of special germ line-encoded 
pathogen-pattern recognition recep-
tors called Toll-like receptors (TLRs). It 
appears that TLRs control activation of 
adaptive immune responses.1 To date, 11 
human and 9 murine proteins related to 
the Drosophila Toll gene have been char-
acterized.1–3 Th ese receptors specifi cally 
recognize pathogen-associated molecular 
patterns that are expressed on or in infec-
tious agents, including lipopolysaccharide, 
lipoprotein, peptidoglycan, bacterial DNA, 
and viral double-stranded RNA.1–3 Upon 
ligand binding, TLR-mediated signaling 
activates signal transduction pathways 
(such as nuclear factor-κB, c-Jun NH2-
terminal kinase/p38, nuclear factor/inter-
leukin-6, and interferon regulatory factor) 
that induce cytokines, chemokines, and 
increased expression of cellular mem-
brane proteins related to infl ammatory 
responses.1–3 Identifying endogenous 
ligands has generated evidence that TLR 
signaling contributes to infl ammation in 
the absence of microbes. Th ese ligands 
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